Related Experiment Video

Updated: Aug 24, 2026

Biventricular Assessment of Cardiac Function and Pressure-Volume Loops by Closed-Chest Catheterization in Mice
08:21

Biventricular Assessment of Cardiac Function and Pressure-Volume Loops by Closed-Chest Catheterization in Mice

Published on: June 15, 2020

The role and assessment of ventricular peptides in heart failure

William E Winter1, Ronald J Elin

  • 1Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Box 100275, Gainesville, FL 32610-0275, USA. winter@pathology.ufl.edu

Clinics in Laboratory Medicine
|May 26, 2004
PubMed

Insights

Diagnosing early heart failure is challenging. This article explores using ventricular natriuretic peptides as a simple, rapid, and objective test for early heart failure detection.

Area of Science:

  • Cardiology and Clinical Biochemistry
  • Biomarker Discovery and Validation

Background:

  • Early-stage heart failure diagnosis presents clinical challenges.
  • Current diagnostic methods may lack simplicity, speed, or objectivity for early detection.
  • A need exists for accessible, reliable heart failure diagnostic tools.

Purpose of the Study:

  • To review the role of natriuretic peptides in heart failure.
  • To assess the utility of ventricular natriuretic peptides and related peptides as diagnostic markers.
  • To highlight the potential for a simple, rapid, and objective heart failure test.

Main Methods:

  • Literature review and synthesis of existing research on natriuretic peptides.
  • Discussion of the assessment methodologies for these peptides.
  • Analysis of peptide roles in the pathophysiology of heart failure.

Main Results:

  • Ventricular natriuretic peptides show significant potential as biomarkers for heart failure.
  • These peptides offer a promising avenue for objective assessment.
  • Related peptides also contribute to understanding heart failure markers.

Conclusions:

  • Natriuretic peptides are valuable indicators in heart failure diagnosis.
  • Their assessment can lead to improved diagnostic capabilities.
  • Further development could yield an inexpensive, rapid, and objective test for heart failure.

More Related Videos

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment08:49

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment

Published on: August 2, 2024

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...